Animal models of CNS disorders

Biochemical Pharmacology

Volumn 87, Issue 1, 2014, Pages 140-149

  McGonigle, Paul ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Neurodegenerative; Neuropsychiatric; Pain; Stroke; Transgenic

Indexed keywords

ALZHEIMER DISEASE; ANIMAL MODEL; ANXIETY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; DEPRESSION; HUNTINGTON CHOREA; NONHUMAN; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TRANSGENIC ANIMAL;

NEURODEGENERATIVE; NEUROPSYCHIATRIC; PAIN; STROKE; TRANSGENIC;

ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 84892371678     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.06.016     Document Type: Review

References (98)

1. E.J. Nestler, and S.E. Hyman Animal models of neuropsychiatric disorders Nat Neurosci 13 2010 1161 1169
2. R.D. Porsolt, M. LePichon, and M. Jalfre Depression: a new animal model sensitive to antidepressant treatment Nature 266 1977 730 732 (Pubitemid 8073804)
3. I. Lucki The forced swimming test as a model for core and component behavioral effects of antidepressant drugs Behav Pharmacol 8 1997 523 532 (Pubitemid 27504702)
4. S.B. Powell, X. Zhou, and M.A. Geyer Prepulse inhibition and genetic mouse models of schizophrenia Behav Brain Res 204 2009 282 294
5. L. Menalled, and M-F. Cesselet Mouse models of Huntington's disease Trends Pharmacol Sci 23 2002 32 39 (Pubitemid 34135973)
6. L. Mangiarini, K. Sathasivam, M. Seller, B. Cozens, A. Harper, and C. Hetherington et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87 1996 493 506 (Pubitemid 26374323)
7. A. Kuhn, D.R. Goldstein, A. Hodges, A.D. Strand, T. Sengstag, and C. Kooperberg et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage Hum Mol Genet 16 2007 1845 1861 (Pubitemid 47244533)
8. A.D. Strand, Z.C. Baquet, A.K. Aragaki, P. Holmans, L. Yang, and C. Cleren et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration J Neurosci 27 2007 11758 11768 (Pubitemid 350006916)
9. A.B.P. Fernando, and T.W. Robbins Animal models of neuropsychiatric disorders Annu Rev Clin Psychol 7 2011 39 61
10. H. Zhou, C. Huang, H. Chen, D. Wang, C.P. Landel, and P.Y. Xia et al. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene PLoS Genet 6 2010 e1000887
11. S. von Horsten, I. Schmitt, H.P. Nguyen, C. Holzmann, and T. Schmidt et al. Transgenic rat model of Huntington's disease Hum Mol Genet 12 2003 617 624 (Pubitemid 36372488)
12. R.M. Cohen, K. Rezai-Zadeh, T.M. Weitz, A. Rentsendorj, D. Gate, and I. Spivak et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss J Neurosci 33 2013 6245 6256
13. J.F. Cryan, A. Markou, and I. Lucki Assessing antidepressant activity in rodents: recent developments and future needs Trends Pharmacol Sci 23 5 2002 238 245 (Pubitemid 34465544)
14. I. Lucki A prescription to resist proscriptions for murine models of depression Psychopharmacol 153 2001 395 398 (Pubitemid 32125826)
15. J.F. Cryan, and C. Mombereau In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice Mol Psychiatry 9 2004 326 357 (Pubitemid 38534696)
16. J.F. Cryan, and A. Holmes The ascent of mouse: advances in modelling human depression and anxiety Nat Rev Drug Discov 4 2005 775 790 (Pubitemid 43090498)
17. J.P. Kelly, A.S. Wrynn, and B.E. Leonard The olfactrory bulbectomized rat as a model of depression: an update Pharmacol Ther 74 1997 299 316 (Pubitemid 27425352)
18. P. Willner Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation Psychopharmacol 134 1997 319 329 (Pubitemid 28023396)
19. R.J. Katz Animal model of depression: pharmacological sensitivity of a hedonic deficit Pharmacol Biochem Behav 16 1982 965 968 (Pubitemid 12081655)
20. J.F. Cryan, and F.F. Sweeney The age of anxiety: role of animal models of anxiolytic action in drug discovery Br J Pharmacol 164 2011 1129 1161
21. R.J. Rodgers Animal models of 'anxiety': where next Behav Pharmacol 8 1997 477 496 (Pubitemid 27504695)
22. G. Griebel, C. Belzung, G. Perrault, and D.J. Sanger Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice Psychopharmacol 148 2000 164 170 (Pubitemid 30104138)
23. R. Rodgers Animal tests for anxiety G.F. Koob, M. Le Moal, R.F. Thompson, Encyclopedia of Behavioral Neuroscience 2010 Academic Press Oxford 90 100
24. F. Borsini, J. Podhorna, and D. Marazziti Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacol (Berl) 163 2002 121 141 (Pubitemid 35013604)
25. S.A. Balogh, and J.M. Wehner Inbred mouse strain differences in the establishment of long-term fear memory Behav Brain Res 140 1-2 2003 97 106 (Pubitemid 36321744)
26. A. Mouri, Y. Noda, T. Enomoto, and T. Nabeshima Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment Neurochem Int 51 2007 173 184 (Pubitemid 47176714)
27. C.A. Jones, D.J. Watson, and K.C. Fone Animal models of schizophrenia Br J Pharmacol 164 4 2011 1162 1194
28. H. Moore, J.D. Jentsch, M. Ghajarnia, M.A. Geyer, and A.A. Grace A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia Biol Psychiatry 60 2006 253 264 (Pubitemid 44093447)
29. K.C.F. Fone, and M.V. Porkess Behavioural and neurochemical effects of post-weaning social isolation in rodents - relevance to developmental neuropsychiatric disorders Neurosci Biobehav Rev 32 2008 1087 1102
30. B.K. Lipska, and D.R. Weinberger Delayed-effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviours in the rat Brain Res Dev Brain Res 75 1993 213 222 (Pubitemid 23293572)
31. K.A. Aberg, Y. Liu, and J. Bukszár et al. A comprehensive family-based replication study of schizophrenia genes JAMA Psychiatry 2013 2013 1 9
32. J. Sun, P. Jia, A.H. Fanous, E. van den Oord, and X. Chen et al. Schizophrenia gene networks and pathways and their applications for novel candidate gene selection PLoS One 5 2010 e11351
33. H. Jaaro-Peled, Y. Ayhan, M. Pletnikov, and A. Sawa Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models Schizophr Bull 36 2010 301 313
34. C. O'Tuathaigh, B. Kirby, P. Moran, and J. Waddington Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia Schizophr Bull 36 2010 271 288
35. J.F. Keeler, and T.W. Robbins Translating cognition from animals to humans Biochem Pharmacol 81 2011 1356 1366
36. J.J. Hagan, and D.N.C. Jones Predicting drug efficacy for cognitive deficits in schizophrenia Schizophr Bull 31 2005 830 853 (Pubitemid 41437777)
37. S.B. Floresco, M.A. Geyer, L.H. Gold, and A.A. Grace Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia Schizophr Bull 31 2005 888 894 (Pubitemid 41437783)
38. J.W. Young, S.B. Powell, V. Risbrough, H.M. Marston, and M.A. Geyer Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia Pharmacol Ther 122 2009 150 202
39. R.S. Keefe, R.W. Buchanan, S.R. Marder, N.R. Schooler, A. Dugar, and M. Zivkov et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far Schizophr Bull 39 2013 417 435
40. B. Kirkpatrick, W.S. Fenton, W.T Carpenter Jr., and S.T. Marder The NIMH-MATRICS consensus statement on negative symptoms Schizophr Bull 32 2006 214 219
41. K. Mullane, and M. Williams Alzheimer's therapeutics continued clinical failures question the validity of the amyloid hypothesis - but what lies beyond? Biochem Pharmacol 85 2013 289 305
42. T. Sunderland, P.N. Tariot, H. Weingartner, D.L. Murphy, P.A. Newhouse, and E.A. Mueller et al. Pharmacologic modelling of Alzheimer's disease Prog Neuropsychopharmacol Biol Psychiatry 10 1986 599 610
43. U. Ebert, and W. Kirch Scopolamine models of dementia: electroencephalogram findings and cognitive performance Eur J Clin Invest 28 1998 944 949 (Pubitemid 28521587)
44. A. Toledana, and M.I. Álvarez Lesion-induced vertebrate models of Alzheimer dementia P.P. De Deyn, D. Van Dam, Animal Models of Dementia 2010 Springer Science + Business Media New York 295 345
45. J. Birks Cholinesterase inhibitors for Alzheimer's disease Cochrane Database 1391 System Rev 1 2006 CD005593
46. D. Van Dam, and P.P. De Deyn Animal models in the drug discovery pipeline for Alzheimer's disease Br J Pharmacol 164 2011 1285 1300
47. A.M. Hall, and E.D. Roberson Mouse models of Alzheimer's disease Brain Res Bull 88 2012 3 12
48. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, and S. Younkin et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice Science 274 1996 99 102 (Pubitemid 26332733)
49. L. Holcomb, M.N. Gordon, E. McGowan, X. Yu, S. Benkovic, and P. Jantzen et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes Nat Med 4 1998 97 100 (Pubitemid 28133087)
50. H. Oakley, S.L. Cole, S. Logan, E. Maus, P. Shao, and J. Craft et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation J Neurosci 26 2006 10129 10140 (Pubitemid 44527407)
51. J.J. Sabbagh, J.W. Kinney, and J.L. Cummings Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications Neurobiol Aging 34 2013 169 183
52. S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, and R. Kayed et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction Neuron 39 2003 409 421 (Pubitemid 36937044)
53. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
54. C. Zuccato, M. Valenza, and C. Cattaneo Molecular mechanisms and potential therapeutic targets in Huntington's disease Physiol Rev 90 2010 905 981
55. R.J. Ferrante Mouse models of Huntington's disease and methodological considerations for therapeutic trials Biochim Biophys Acta 1792 2009 506 520
56. R.J. Ferrante, N.W. Kowall, P.B. Cipolloni, E. Storey, and M.F. Beal Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization Exp Neurol 119 1993 46 71 (Pubitemid 23074242)
57. M.F. Beal, R.J. Ferrante, K.J. Swartz, and N.W. Kowall Chronic quinolinic acid lesions in rats closely resemble Huntington's disease J Neurosci 11 1991 1649 1659
58. Z.R. Crook, and D. Housman Huntington's disease: can mice lead the way to treatment? Neuron 69 2011 423 435
59. L. Menalled, B.F. El-Khodor, M. Patry, M. Suárez-Fariñas, S.J. Orenstein, and B. Zahasky et al. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models Neurobiol Dis 35 2009 319 336
60. S. Frank Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators BMC Neurol 9 2009 62
61. H. Wang, X. Chen, Y. Li, T.-S. Tang, and I. Bezprozvanny Tetrabenazine is neuroprotective in Huntington's disease mice Mol Neurodegener 5 2010 18
62. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909 (Pubitemid 37130207)
63. J. Blesa, S. Phani, V. Jackson-Lewis, and S. Przedborski Classic and new animal models of Parkinson's disease J Biomed Biotechnol 2012 2012 845618
64. R.J. Tolwani, M.W. Jakowec, G.M. Petzinger, S. Green, and K. Waggie Experimental models of Parkinson's disease: insights from many models Lab Anim Sci 49 1999 363 371 (Pubitemid 29411753)
65. S. Duty, and P. Jenner Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease Br J Pharmacol 164 2011 1357 1391
66. P. Waldmeier, D. Bozyczko-Coyne, M. Williams, and J.L. Vaught Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases Biochem Pharmacol 72 2006 1197 1206 (Pubitemid 44604283)
67. Y. Lee, V.L. Dawson, and T.M. Dawson Animal models of Parkinson's disease: vertebrate genetics Cold Spring Harb Perspect Med 2 2012 1 12
68. M.F. Chesselet, S. Fleming, F. Mortazavi, and B. Meurers Strengths and limitations of genetic mouse models of Parkinson's disease Parkinsonism Relat Disord 14 2008 S84 S87
69. S. Biskup, D.J. Moore, F. Celsi, S. Higashi, A.B. West, and S.A. Andrabi et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain Ann Neurol 60 2006 557 569 (Pubitemid 44871798)
70. T.M. Dawson, H.S. Ko, and V.L. Dawson Genetic animal models of Parkinson's disease Neuron 66 5 2010 646 661
71. C.B. Johannes, T.K. Le, X. Zhou, J.A. Johnston, and R.H. Dworkin The prevalence of chronic pain in United States adults: results of an internet-based survey J Pain 11 2010 1230 1239
72. J.S. Mogil Animal models of pain: progress and challenges Nature Rev Neurosci 10 2009 283 294
73. J. Sandkuhler Models and mechanisms of hyperalgesia and allodynia Physiol Rev 89 2009 707 758
74. O.-G. Berge Predictive validity of behavioral animal models for chronic pain Brit J Pharm 164 2011 1195 1206
75. A.S. Jaggi, V. Jain, and N. Singh Animal models of neuropathic pain Fund Clin Pharm 25 2011 1 28
76. T. Dowdall, I. Robinson, and T.F. Meert Comparison of five different rat models of peripheral nerve injury Pharmacol Biochem Behav 80 2005 93 108 (Pubitemid 40126207)
77. G.J. Bennett, and Y.K. Xie A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man Pain 33 1988 87 107
78. S.H. Kim, and J.M. Chung An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat Pain 50 1992 355 363
79. K.J. Kim, Y.W. Yoon, and J.M. Chung Comparison of three rodent neuropathic pain models Exp Brain Res 113 1997 200 206 (Pubitemid 27090842)
80. R.C. Polomanoa, A.J. Mannes, U.S. Clark, and G.J. Bennett A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel Pain 94 2001 293 304 (Pubitemid 33145399)
81. C. Courteix, A. Eschalier, and J. Lavarenne Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain Pain 53 1993 81 88 (Pubitemid 23137271)
82. M.J. Schwei, P. Honore, S.D. Rogers, J.L. Salak-Johnson, M.P. Finke, and M.L. Ramnaraine et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain J Neurosci 19 1999 10886 10897 (Pubitemid 30235733)
83. S.E. Bove, S.J. Flatters, J.J. Inglis, and P.W. Mantyh New advances in musculoskeletal pain Brain Res Rev 60 2009 187 201
84. C. Pacharinsak, and A. Beitz Animal Models of Cancer Pain Comp Med 58 2008 220 233 (Pubitemid 351954728)
85. D.A. Kalbhen Chemical model of osteoarthritis - a pharmacological evaluation J Rheumatol 14 1987 130 131 (Pubitemid 17156583)
86. R. Hill NK1 (substance P) receptor antagonists - why are they not analgesic in humans? Trends Pharmacol Sci 21 2000 244 246 (Pubitemid 30445249)
87. G.T. Whiteside, A. Adedoyin, and L. Leventhal Predictive validity of animal pain models? A comparison of the pharmacokinetic-pharmacodynamic relationship for pain drugs in rats and humans Neuropharmacol 54 2008 767 775
88. T.J. Martin, S.A. Kim, N.L. Buechler, F. Porreca, and J.C. Eisenach Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics Anesthesiol 106 2007 312 322 (Pubitemid 46185177)
89. T. King, L. Vera-Portocarrero, T. Gutierrez, T.W. Vanderah, G. Dussor, and J. Lai et al. Unmasking the tonic-aversive state in neuropathic pain Nat Neurosci 12 2009 1364 1366
90. R.M. Crowell, F.W. Marcoux, and U. DeGirolami Variability and reversibility of focal ischemia in unanesthetized monkeys Neurology 31 1981 1295 1302 (Pubitemid 11026848)
91. D.W. Howells, M.J. Poritt, S.S.J. Rewell, V. O'Collins, E.S. Sena, and H.B. van der Worp et al. Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia J Cereb Blood Flow and Metab 30 2010 1412 1431
92. J. Koizumi, Y. Yoshida, T. Nakazawa, and G. Ooneda Experimental studies of ischemic brain edema. 1. A new experimental model of experimental embolism in rats in which recirculation can be reintroduced in the ischemic area Jpn J Stroke 8 1986 1 8
93. G.A. Donnan, M. Fisher, M. MacLeod, and Davis S.M. Stroke Lancet 371 2008 1612 1623 (Pubitemid 351626845)
94. M. Kudo, A. Aoyama, S. Ichimori, and N. Fukunaga An animal model of cerebral infarction. Homologous blood clot emboli in rats Stroke 13 1982 505 508
95. V.E. O'Collins, M.R. Macleod, G.A. Donnan, L.L. Horky, B.H. van der Worp, and D.W. Howells 1026 experimental treatments in acute stroke Ann Neurol 59 2006 467 477 (Pubitemid 43358067)
96. R.A. MacArthur, and F. Borsini Animal and Translational Models for CNS Drug Discovery 2008 Elsevier Inc. San Diego, CA
97. H.C. Yan, X. Cao, M. Das, X.H. Zhu, and T.M. Gao Behavioral animal models of depression Neurosci Bull 26 4 2010 327 337
98. J.F. Cryan, C. Mombereau, and A. Vassout The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice Neurosci Behav Rev 29 2005 571 625 (Pubitemid 40755457)